Ulrike Philippar, Lorena Fontan, Min Xia, Nele Vloemans, Mariette Bekkers, Marcello Gaudiano, Onyi Irrechukwu, Diede van den Biggelaar, Tatiana Perova, Irene Guimerans-Lorenzo, Katarzyna Wnuk-Lipinska, Ivo Cornelissen, Marjolein van Heerden, Bas-Jan van der Leede, Katie Amssoms, Rui Xu, Joanna Grant, Emanuele Trella, Yann Abraham, Kristof Kimpe, Bart Medaer, Anthony Greway, Jan Snoeys, Frank Jacobs, Maxwell D Cummings, Weimei Sun, Jan Willem Thuring, Tongfei Wu, Stan Gaj, Bie Verbist, Peter J Connolly, Nigel Austin, Sriram Balasubramanian, Jacqueline Kinyamu-Akunda, Kathryn Packman, James P Edwards, Yusri Elsayed, Nele Fourneau, Franck Morschhauser, John F Gerecitano, Jacqueline Bussolari, Ari M Melnick, Ricardo M Attar
{"title":"Preclinical characterization of the potent and selective MALT1 inhibitor safimaltib in B-cell lymphoma models.","authors":"Ulrike Philippar, Lorena Fontan, Min Xia, Nele Vloemans, Mariette Bekkers, Marcello Gaudiano, Onyi Irrechukwu, Diede van den Biggelaar, Tatiana Perova, Irene Guimerans-Lorenzo, Katarzyna Wnuk-Lipinska, Ivo Cornelissen, Marjolein van Heerden, Bas-Jan van der Leede, Katie Amssoms, Rui Xu, Joanna Grant, Emanuele Trella, Yann Abraham, Kristof Kimpe, Bart Medaer, Anthony Greway, Jan Snoeys, Frank Jacobs, Maxwell D Cummings, Weimei Sun, Jan Willem Thuring, Tongfei Wu, Stan Gaj, Bie Verbist, Peter J Connolly, Nigel Austin, Sriram Balasubramanian, Jacqueline Kinyamu-Akunda, Kathryn Packman, James P Edwards, Yusri Elsayed, Nele Fourneau, Franck Morschhauser, John F Gerecitano, Jacqueline Bussolari, Ari M Melnick, Ricardo M Attar","doi":"10.1158/2643-3230.BCD-26-0182","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-26-0182","url":null,"abstract":"<p><p>Constitutive activation of the B-cell receptor (BCR) pathway drives non-Hodgkin lymphomas. MALT1 is a key mediator of NF-κB signaling downstream of B- and T-cell receptors. Herein, we report development of safimaltib (JNJ-67856633), a selective, allosteric inhibitor of MALT1 protease. The crystal structure of safimaltib bound to MALT1 was determined, and enzyme kinetic studies were performed to characterize its inhibitory mechanism. Sub-micromolar doses of safimaltib inhibited growth of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cell lines with activation of NF-κB signaling and models mimicking BTK inhibition resistance. Notably, activating mutations in BCR-pathway components were strongly associated with safimaltib response in vitro. Safimaltib demonstrated efficacy in DLBCL and MCL mouse models and synergy with a BTK inhibitor. Safimaltib was well tolerated in preclinical immunocompetent animal models with a safety profile supporting MALT1 targeting in humans. Overall, these results provide rationale for the first-in-human MALT1 inhibitor clinical trial.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":""},"PeriodicalIF":12.2,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149380885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ruwan Gunaratne, Crystal M Zhou, Sanjeeth Rajaram, Jesse W Tai, Kailee L Tanaka, Charu Tiwari, Emily Y Yang, Sky Kim, Grace Gao, Raymond Yin, Mia Carleton, Matthew S Alkaitis, Matthew Schwede, Brian J Sworder, Gabriel N Mannis, Michael S Khodadoust, Ravindra Majeti, David M Kurtz, Tian Yi Zhang
{"title":"Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia.","authors":"Ruwan Gunaratne, Crystal M Zhou, Sanjeeth Rajaram, Jesse W Tai, Kailee L Tanaka, Charu Tiwari, Emily Y Yang, Sky Kim, Grace Gao, Raymond Yin, Mia Carleton, Matthew S Alkaitis, Matthew Schwede, Brian J Sworder, Gabriel N Mannis, Michael S Khodadoust, Ravindra Majeti, David M Kurtz, Tian Yi Zhang","doi":"10.1158/2643-3230.BCD-26-0159","DOIUrl":"10.1158/2643-3230.BCD-26-0159","url":null,"abstract":"<p><p>Relapsed and/or refractory disease remains the leading cause of death in acute myeloid leukemia (AML), highlighting the need for broadly applicable, high-sensitivity approaches to measurable residual disease (MRD) detection. We developed AML-Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq), a personalized hybrid-capture assay that tracks both canonical AML drivers and patient-specific variants identified by whole-exome sequencing. In 56 patients with longitudinal plasma and matched peripheral blood and bone marrow samples, AML-CAPP-Seq enabled universal MRD assessment and resolution of clonal dynamics using a median of 30.5 variants per patient. Plasma circulating tumor DNA (ctDNA) outperformed cellular compartments for MRD detection and more strongly predicted relapse-free survival [hazard ratio (HR), 17.8; P < 0.0001] and overall survival (HR, 17; P < 0.0001) than standard-of-care (SOC) MRD methods. Among 29 allogeneic transplant recipients, peritransplant ctDNA-MRD dynamics markedly improved relapse risk stratification (HR, 36; P = 0.0009). Together, these results establish personalized ctDNA profiling as a minimally invasive, highly sensitive, and generalizable platform for enhanced clinical MRD detection and clonal surveillance in AML.</p><p><strong>Significance: </strong>We present a personalized blood test for AML that tracks patient-specific ctDNA, enabling sensitive, universal, and noninvasive detection of residual disease. It outperforms SOC marrow- and cell-based methods for predicting relapse and survival, including after transplant, reveals clonal dynamics, and supports individualized disease monitoring and risk-adapted treatment.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"921-939"},"PeriodicalIF":12.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A (Post)translational Opportunity in RAS-Dependent Heme Malignancy.","authors":"Lawrence H Boise","doi":"10.1158/2643-3230.BCD-26-0319","DOIUrl":"10.1158/2643-3230.BCD-26-0319","url":null,"abstract":"<p><p>Zhang and colleagues uncover a mechanism of regulation of RAS stability that is active almost exclusively in hematologic (heme) malignancies. This provides new insights into the consequences of a RAS hotspot mutation found in leukemia and myeloma and points to a new therapeutic opportunity in these diseases. See related article by Zhang et al., p. 978.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"860-862"},"PeriodicalIF":12.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marnix Koops, Luca Bertamini, Natalie Papazian, Charlotte Korst, Mátyás János Budai, Remco M Hoogenboezem, Mathijs A Sanders, Bronno van der Holt, Mark van Duin, Annemiek Broijl, Péter Balogh, Sonja Zweegman, Marc H G P Raaijmakers, Niels W C J van de Donk, Zoltán Kellermayer, Pieter Sonneveld, Tom Cupedo
{"title":"Spatial Profiling Identifies a Distinct and Topographically Defined Tumor Microenvironment that Emerges during Multiple Myeloma Evolution.","authors":"Marnix Koops, Luca Bertamini, Natalie Papazian, Charlotte Korst, Mátyás János Budai, Remco M Hoogenboezem, Mathijs A Sanders, Bronno van der Holt, Mark van Duin, Annemiek Broijl, Péter Balogh, Sonja Zweegman, Marc H G P Raaijmakers, Niels W C J van de Donk, Zoltán Kellermayer, Pieter Sonneveld, Tom Cupedo","doi":"10.1158/2643-3230.BCD-26-0080","DOIUrl":"10.1158/2643-3230.BCD-26-0080","url":null,"abstract":"<p><p>The pathobiology of multiple myeloma is influenced by cells of the bone marrow (BM), but whether tumor support is organized in a spatially defined tumor microenvironment (TME) remains unclear. Using spatial transcriptomics and imaging mass cytometry, we show that myeloma cells initially exist as scattered cells throughout the marrow, yet with disease evolution condense into a spatially defined TME. Dense tumor nodules contain a cellular ecosystem distinct from the surrounding marrow, enriched for macrophages, conventional dendritic cells, and CD8+ T cells, as well as endothelial cells and THY1+ mesenchymal stromal cells. Conversely, neutrophil lineage cells are absent from this TME but interact with scattered myeloma cells outside of dense nodules. The presence of the dense tumor architecture at diagnosis confers a worse prognosis, emphasizing the relevance of spatial organization of the BM. Together, these findings define a discrete spatial and cellular myeloma TME that provides spatially guided insights into patient stratification and disease pathobiology.</p><p><strong>Significance: </strong>This study provides identification of a topographically defined TME for multiple myeloma, with a specific cellular ecosystem. This TME develops during disease evolution and is linked to worse outcomes in newly diagnosed patients. Our work provides insight into the interplay of tumor evolution and spatial organization in multiple myeloma.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"999-1016"},"PeriodicalIF":12.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148867041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ruixian Xing, Apeng Yang, Juan Huang, Liang Wang, Wei Guo, Qu Cui, Xiaoqiong Tang, Yuanyuan Ma, Kai Hu, Tianheng He, Danyang Wu, Xiaofang Deng, Yajing Zhang, Kaili Zhong, Yang Liu, Yixian Guo, Ying Wang, Chan Long, Chongyang Wu, Xin Lu, Fengmin Li, Jiefei Bai, Jun Qian, Xuefei Sun, Wenrong Huang, Hui Zhou, Huilai Zhang, Ou Bai, Xiaobing Huang, Zhiyong Zeng, Lin Fu
{"title":"Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study.","authors":"Ruixian Xing, Apeng Yang, Juan Huang, Liang Wang, Wei Guo, Qu Cui, Xiaoqiong Tang, Yuanyuan Ma, Kai Hu, Tianheng He, Danyang Wu, Xiaofang Deng, Yajing Zhang, Kaili Zhong, Yang Liu, Yixian Guo, Ying Wang, Chan Long, Chongyang Wu, Xin Lu, Fengmin Li, Jiefei Bai, Jun Qian, Xuefei Sun, Wenrong Huang, Hui Zhou, Huilai Zhang, Ou Bai, Xiaobing Huang, Zhiyong Zeng, Lin Fu","doi":"10.1158/2643-3230.BCD-26-0128","DOIUrl":"10.1158/2643-3230.BCD-26-0128","url":null,"abstract":"<p><p>Relapsed or refractory central nervous system lymphoma (R/R CNSL) has limited treatment options. This multicenter retrospective study enrolled 84 consecutive patients with R/R CNSL [median age, 59 years; median of 2.5 prior lines of therapy; 53 primary CNSL (PCNSL) and 31 secondary CNSL (SCNSL)] to evaluate the efficacy and safety profiles of glofitamab therapy. For PCNSL, the objective response rate (ORR) was 88% and complete response rate (CRR) was 59% with glofitamab monotherapy (n = 32) and 100% and 81% with combination therapy (n = 21), respectively. For SCNSL, ORR and CRR were 88% and 75% with glofitamab monotherapy (n = 8) and 91% and 65% with combination therapy (n = 23). At 14.7 months of follow-up, median progression-free survival was 19.5 months for PCNSL and 13.5 months for SCNSL. Cytokine release syndrome occurred in 40% (all grades 1-2) of patients, and immune effector cell-associated neurotoxicity syndrome occurred in 8%. Glofitamab-based therapy demonstrated substantial activity with manageable toxicity in this study, offering a promising treatment paradigm for patients with R/R CNSL.</p><p><strong>Significance: </strong>Effective therapies are urgently needed for R/R CNSL. Glofitamab-based therapy demonstrated high response rates in PCNSL (ORR, 92%; CRR, 68%) and SCNSL (ORR, 90%; CRR, 68%) with manageable toxicity in 84 consecutive, heavily pretreated patients, establishing a promising treatment option for this high-risk population.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"909-920"},"PeriodicalIF":12.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Trieu H Nguyen, Jessica Jeejan, Takeshi Iwasaki, Susan Kales, Joyeeta Chakraborty, Chie Yanase, Aruna Shekhar, Dominika Kwasniak, Aditi Hegde, Richard A Voit, Joshua Weinstock, Kristy R Stengel, Keisuke Ito, Ryan Tewhey, Satish K Nandakumar
{"title":"Germline Noncoding Risk Variants Influence Clonal Hematopoiesis through Altered Hematopoietic Enhancer Activity.","authors":"Trieu H Nguyen, Jessica Jeejan, Takeshi Iwasaki, Susan Kales, Joyeeta Chakraborty, Chie Yanase, Aruna Shekhar, Dominika Kwasniak, Aditi Hegde, Richard A Voit, Joshua Weinstock, Kristy R Stengel, Keisuke Ito, Ryan Tewhey, Satish K Nandakumar","doi":"10.1158/2643-3230.BCD-26-0046","DOIUrl":"10.1158/2643-3230.BCD-26-0046","url":null,"abstract":"<p><p>Clonal hematopoiesis of indeterminate potential (CHIP) is a precursor condition characterized by the expansion of mutant hematopoietic stem and progenitor cell (HSPC) clones that increase the risk of hematologic malignancies. Although genome-wide association studies have identified multiple noncoding loci associated with CHIP susceptibility, their mechanisms remain unclear. We hypothesized that CHIP risk variants alter enhancer activity in HSPCs. To test this, we screened 1,374 noncoding variants from 51 CHIP-associated loci using a massively parallel reporter assay (MPRA) in the CD34+ fraction of MUTZ-3 cells. We identified 87 regulatory variants across 32 loci. Targeted genome editing in hematopoietic cells and complementary reporter assays in primary human HSPCs validated enhancer activity for variants regulating NKD2, FLT3, and MSI2. Functional studies demonstrated that increased MSI2 expression, modeling the effect of the CHIP risk allele, promotes clonal expansion of Tet2-deficient HSPCs, providing a mechanistic link between inherited noncoding variation and CHIP clonal expansion.</p><p><strong>Significance: </strong>An MPRA was used to screen 1,374 noncoding germline variants associated with clonal hematopoiesis risk. Eighty-seven expression-modulating variants were identified by the MPRA, including an MSI2 enhancer variant that influences the expansion of Tet2-mutant HSPCs.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"1017-1032"},"PeriodicalIF":12.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148888313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All.","authors":"Eric Perkey, Justin Kline","doi":"10.1158/2643-3230.BCD-26-0260","DOIUrl":"10.1158/2643-3230.BCD-26-0260","url":null,"abstract":"<p><p>In this issue of Blood Cancer Discovery, Corona, Gillmor, and colleagues show that quantitative CD19 density measured before chimeric antigen receptor (CAR) T-cell infusion stratifies progression-free survival in large B-cell lymphoma, yet low antigen density rarely reflects a genetic lesion at the CD19 locus itself, suggesting that other mechanisms of CD19 downregulation may promote CAR T-cell escape. Moreover, Newsam and colleagues offer one explanation-recurrent del(3p21.31)/RHOA loss that results in decreased CD19 in trans and impairs CAR T-cell efficacy. See related article by Corona et al., p. 940 See related article by Newsam et al., p. 957.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"852-855"},"PeriodicalIF":12.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lin Zhang, Arnold Bolomsky, Omar S Al-Odat, Callie K VanWinkle, Aaliyah Battle, Papiya Chakraborty, Ronald J Holewinski, Thorkell Andresson, Björn Häupl, Thomas Oellerich, Elizabeth Hill, Mehmet Kocoglu, Qingcai Meng, James D Phelan, Jagan Muppidi, Ryan M Young
{"title":"Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.","authors":"Lin Zhang, Arnold Bolomsky, Omar S Al-Odat, Callie K VanWinkle, Aaliyah Battle, Papiya Chakraborty, Ronald J Holewinski, Thorkell Andresson, Björn Häupl, Thomas Oellerich, Elizabeth Hill, Mehmet Kocoglu, Qingcai Meng, James D Phelan, Jagan Muppidi, Ryan M Young","doi":"10.1158/2643-3230.BCD-26-0028","DOIUrl":"10.1158/2643-3230.BCD-26-0028","url":null,"abstract":"<p><p>Oncogenic KRAS and NRAS mutations are common in hematologic malignancies, but their signaling in this context remains less well characterized than in carcinomas. Using multiomics screens in multiple myeloma, we sought to identify regulators of RAS activity. We found that the phosphatase PP1C dephosphorylated conserved RAS residue T148, permitting LZTR1-dependent proteasomal degradation. LZTR1 was ineffective against KRAS A146 gain-of-function mutations, which lie adjacent to T148 and are enriched in hematologic cancers, such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML). Remarkably, KRAS protein stability was 4-fold lower in hematologic versus carcinoma cells, revealing a unique therapeutic opportunity targeting RAS protein stability. PAK1 and PAK2 shielded RAS from LZTR1-dependent degradation by phosphorylating T148, and inhibiting PAK1/2 activity improved RAS-directed therapy. Collectively, these findings reveal a regulatory circuit governing RAS stability that is preferentially active in blood cancers and potentially druggable.</p><p><strong>Significance: </strong>We found that PP1C and PAK1/2 regulate RAS T148 phosphorylation, controlling LZTR1-mediated RAS degradation in multiple myeloma, DLBCL, and AML. PAK1/2 inhibition reduces RAS expression, enhancing the efficacy of RAS-directed therapies in multiple myeloma. Notably, KRAS A146 mutations, prevalent in blood cancers, can shield RAS from this degradation. See related commentary by Boise, p. 860.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"978-998"},"PeriodicalIF":12.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qingyu Luo, Karley S Whalen, Xiaowei Wu, Amanda L Fortune, Jacqueline S Garcia, Kate Marinchev, Lin Zhang, Weiye Qian, Evangeline G Raulston, Yabing Nan, Christopher A G Booth, Kezhi Yan, David E Root, John G Doench, Andrew A Lane
{"title":"Therapy-Persistent Leukemia Is Selectively Vulnerable to SLC23A1 Restoration via Targeting KHSRP.","authors":"Qingyu Luo, Karley S Whalen, Xiaowei Wu, Amanda L Fortune, Jacqueline S Garcia, Kate Marinchev, Lin Zhang, Weiye Qian, Evangeline G Raulston, Yabing Nan, Christopher A G Booth, Kezhi Yan, David E Root, John G Doench, Andrew A Lane","doi":"10.1158/2643-3230.BCD-26-0030","DOIUrl":"10.1158/2643-3230.BCD-26-0030","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is prone to relapse driven by therapy-persistent residual cells. To discover specific vulnerabilities in this population, we performed genome-wide CRISPR interference screens in leukemia cells treated with multiple agents. KHSRP was the top hit, the depletion of which sensitized AML cells to therapy and substantially prolonged survival in treated AML-bearing mice. Analysis of in vivo residual disease after venetoclax/azacitidine treatment identified downregulation of the vitamin C and uric acid transporter SLC23A1, which mediated resistance to multiple therapies. KHSRP depletion restored SLC23A1 expression by preventing its ZC3H4-mediated nuclear mRNA degradation. KHSRP depletion therefore enhanced the synergistic cytotoxicity of vitamin C and uric acid, particularly in therapy-persistent leukemia cells. Re-expression of TET2 overrode the chemosensitizing effect of KHSRP depletion in TET2-mutant leukemia, suggesting that KHSRP-linked phenotypes were related to vitamin C- and uric acid-mediated TET activation. These findings suggest targeting KHSRP to enhance treatment efficacy and selectively eradicate residual AML.</p><p><strong>Significance: </strong>Residual AML cells that persist following therapy have distinct biological properties compared with initial disease or overt relapse. Here, we nominate KHSRP as a target to improve therapy efficacy and exploit selective vulnerabilities of AML residual disease.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"878-891"},"PeriodicalIF":12.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148881910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Magdalena Corona, Aaron Gillmor, Kimon V Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B Dahi, Anthony F Daniyan, Mark T A Donoghue, Sigrun Einarsdottir, Lorenzo Falchi, Qi Gao, Gregory Goldgof, Marina Gomez-Llobell, Erel Joffe, Richard J Lin, Alejandro Luna de Abia, Efrat Luttwak, M Lia Palomba, Jae H Park, Sandeep S Raj, Kai Rejeski, Alfredo Rivas-Delgado, Gilles Salles, Jaime Sanz, Michael Scordo, Gunjan L Shah, Sulov Chalise, Manik Uppal, Anna Gurevich-Shapiro, Menglei Zhu, Miguel-Angel Perales, Allison L Richards, Mikhail Roshal, Roni Shouval
{"title":"Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma.","authors":"Magdalena Corona, Aaron Gillmor, Kimon V Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B Dahi, Anthony F Daniyan, Mark T A Donoghue, Sigrun Einarsdottir, Lorenzo Falchi, Qi Gao, Gregory Goldgof, Marina Gomez-Llobell, Erel Joffe, Richard J Lin, Alejandro Luna de Abia, Efrat Luttwak, M Lia Palomba, Jae H Park, Sandeep S Raj, Kai Rejeski, Alfredo Rivas-Delgado, Gilles Salles, Jaime Sanz, Michael Scordo, Gunjan L Shah, Sulov Chalise, Manik Uppal, Anna Gurevich-Shapiro, Menglei Zhu, Miguel-Angel Perales, Allison L Richards, Mikhail Roshal, Roni Shouval","doi":"10.1158/2643-3230.BCD-25-0501","DOIUrl":"10.1158/2643-3230.BCD-25-0501","url":null,"abstract":"<p><p>It remains uncertain whether lower CD19 expression is clinically relevant for outcomes of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL). We conducted an integrative analysis of tumor CD19 levels with centralized quantitative assessment by flow cytometry (FC), immunohistochemistry (IHC), and RNA sequencing (RNA-seq) in an LBCL cohort (n = 301). Pretreatment CD19 by FC correlated with 1-year progression-free survival following axicabtagene ciloleucel or lisocabtagene maraleucel (16%, 53%, and 64% for CD19low, CD19intermediate, and CD19high, respectively; P = 0.005). After CAR-T relapse, the proportion of CD19low tumors increased (from 17% to 35%). Concordant associations were observed by IHC and RNA-seq. Transcriptomic profiling linked lower CD19 to inflammatory pathways, validated in an external LBCL cohort (n = 1,017). Genetic loss of the CD19 locus was observed in 8% of pre-CAR-T tumors and 11% of post-CAR-T tumors (P = 0.82), whereas no CD19 coding mutations were identified. Overall, CD19 expression is a clinically meaningful determinant of CAR-T outcomes, supporting quantitative assessment to improve risk stratification.</p><p><strong>Significance: </strong>CD19 expression reflects clinical outcomes of CD19-directed CAR-T therapy in LBCL. Standardized, quantitative assessment-particularly by FC-identifies patients at higher risk of treatment failure, informs post-CAR-T relapse biology, and provides actionable insights to guide risk stratification and therapeutic decision-making in routine clinical practice. See related commentary by Perkey and Kline, p. 852.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"940-956"},"PeriodicalIF":12.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148867058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}